Welcome to BioSeeker Group!

Melanoma - Targeted Therapeutics

Additional Information

Published Date Jul 19, 2007
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 197
PDF Fact Sheet View Fact Sheet for the report Melanoma - Targeted Therapeutics in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Melanoma - Targeted Therapeutics.

    To find out more about Melanoma - Targeted Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Melanoma - Targeted Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. In the current alternatives for the treatment of malignant melanoma several combinatory treatments are used. Melanoma drug development has and will continue to have a strong focus on target therapy such as cancer vaccines, monoclonal antibodies, biological drugs, antiangiogenesis, apoptotic inducers and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells and antiangiogenesis.

This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments.

This report covers the latest on:

  • Analysis of current treatment and key therapeutic strategies
  • Progress analysis of on more than 50 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
  • Enables competitive landscape analysis
  • Achievements from the most important companies in melanoma R&D

Example of drugs included in this analysis:

ABX MA1, Alfanative , ALLOVECTIN-7, AP 12009, Avastin, BAY 504798, Canvaxin, Carboplatin, Carmustine, Ceplene Maxamine, Cisplatin, CP 4055, Dacarbazine, Dexosome, Didemnin B, Ecromeximab, Elea Vaccine, EMD 273063, Enhanzyn, F 50040, Genasense, GMK, GV 1001, GVAX, Iboctadekin, ILX 651, INGN 241, INO 1001, Intron A, Kahalalide F, Karenitecin, KOS 953, Lenalidomide, Lomeguatrib, MDX-010, Melacine, Melphalan, MJV 101, M-VAX, NOVOVAC-M1, NY-ESO-1 ISCOMS, Oncophage, OncoVax, OncoVEXGM-CSF, Paclitaxel, PD 0325901, Peginterferon alfa-2b, Pivanex, Proleukin , ProMune, QS-21, SB 249553, SB 715992, Sorafenib, Talabostat, Tamoxifen, Temozolomide, Temozolomide, Uvidem, Vinblastine/Vinorelbine, Virulizin, Vitaxin, Zadaxin

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 4.1 List of Boxes
4.2 List of Tables
5 Etiology and Pathophysiology
6 Current Treatment Strategies
6.1 An Overview
6.2 Cytotoxic Drugs
6.2.1 Dacarbazine
6.2.2 Cisplatin
6.2.3 Carboplatin
6.2.4 Carmustine
6.2.5 Melphalan
6.2.6 Paclitaxel
6.2.7 Tamoxifen
6.2.8 Temozolomide
6.2.9 Vinblastine/Vinorelbine
6.3 Biological treatments
6.3.1 Intron A
6.3.2 Virulizin
6.3.3 Melacine
6.3.4 Alfanative (Multiferon)
6.3.5 Proleukin or (Macrolin)
6.3.6 Enhanzyn
6.3.7 M-VAX
6.4 Other
6.4.1 Ceplene Maxamine
7 Key Therapy Strategies
7.1 Immunotherapy
7.2 Anti-angiogenesis
7.3 Apoptotic Induction
7.4 Gene Therapy
8 Current Melanoma Drug Development: Late Stage Pipeline
8.1 Immunotherapy
8.1.1 Oncophage
8.1.2 Canvaxin
8.1.3 GMK
8.1.4 MDX-010
8.1.5 OncoVax
8.1.6 ALLOVECTIN-7
8.1.7 Peginterferon alfa-2b
8.2 Anti-angiogenesis
8.2.1 Lenalidomide
8.3 Apoptotic Inducers
8.3.1 Genasense
8.4 Inhibiting Cell Growth
8.4.1 Temozolomide
9 Current Melanoma Drug Development: Early Stage Pipeline
9.1 Immunotherapy
9.1.1 INGN 241
9.1.2 QS-21
9.1.3 Talabostat
9.1.4 SB 249553
9.1.5 GVAX
9.1.6 GV 1001
9.1.7 Dexosome
9.1.8 Uvidem
9.1.9 NY-ESO-1 ISCOMS
9.1.10 NOVOVAC-M1
9.1.11 Oxxon Vaccine
9.1.12 Therion’s Melanoma Vaccine
9.1.13 ImmunoVex trimelan
9.1.14 OncoVEXGM-CSF
9.1.15 Zadaxin
9.1.16 Alvac-Mage1/Mage3
9.1.17 Iboctadekin
9.1.18 ProMune
9.1.19 BAY 504798
9.1.20 EMD 273063
9.2 Antiangiogenesis
9.2.1 Sorafenib
9.2.2 Vitaxin
9.2.3 Avastin
9.2.4 PI
9.3 Apoptotic Inducers
9.3.1 Didemnin B
9.3.2 KOS 953
9.4 Small Molecules Inhibiting Cell Growth
9.4.1 Pivanex
9.4.2 Karenitecin
9.4.3 Lomeguatrib
9.4.4 PD 0325901
9.4.5 SB 715992
9.4.6 INO 1001
9.4.7 CP 4055
9.5 Other Biological Drugs
9.5.1 AP 12009
9.5.2 Ecromeximab
9.5.3 ILX 651
9.5.4 Kahalalide F
9.5.5 ABX MA1
9.5.6 MJV 101
9.5.7 A Russian Melanoma Vaccine
9.5.8 Elea Vaccine
9.5.9 F 50040
10 Appendix I: Treatment Guide Lines Melanoma
11 Disclaimer
12 Drug Index
13 Company Index


4.1 List of Boxes
Box 1: Quick Facts - Enhanzyn
Box 2: Quick Facts - M-VAX
Box 3: M-VAX - Business & Market Bakground
Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
Box 5: Introgen’s INGN 241 Shows Vaccine Properties
Box 6: Quick Facts - Oncophage
Box 7: Oncophage - Designation and Status
Box 8: Quick Facts - Canvaxin
Box 9: Canvaxin - Designation and Status
Box 10: CancerVax Milestone payment
Box 11: Quick Facts - GM2-KLH Vaccine
Box 12: Progenics Reaquires Rights to Vaccine
Box 13: Completed Melanoma Phase III trial
Box 14: Quick Facts - MDX-010
Box 15: Quick Facts -OncoVax
Box 16: Quick Facts - ALLOVECTIN-7
Box 17: Quick Facts - Peginterferon alfa-2b
Box 18: Introgen’s INGN 241 Shows Anti-angiogenesis Properties
Box 19: Quick Facts - Lenalidomide
Box 20: Quick Facts - Oblimersen
Box 21: Quick Facts - Temozomide
Box 22: Molecular Pathways Underlying the Activity of Temozolomide’s Anti-Cancer Therapy
Box 23: Regulatory Progress
Box 24: Quick Facts - INGN 241
Box 25: Molecular Pathways Underlying Activity of Introgen’s INGN 241 Anti-Cancer Therapy
Box 26: Quick Facts - QS-21
Box 27: Quick Facts - Talabostat
Box 28: Quick Facts - SB 249553
Box 29: Quick Facts - GVAX
Box 30: Agreement Japan Tobacco and Cell Genesys
Box 31: Predicted launch of GVAX
Box 32: Quick Facts - GV 1001
Box 33: Quick Facts - Dexosome
Box 34: Important Milestones and License Fees
Box 35: Quick Facts - Uvidem
Box 36: Agreements Between Sanofi-Aventis and IDM
Box 37: Quick Facts - NY-ESO-1 ISCOMS
Box 38: NY-ESO-1 and ISCOMATRIX
Box 39: Quick Facts - NovoVac-M1
Box 40: Quick Facts - Oxxon vaccine
Box 41: Quick Facts - Therion’s Melanoma Vaccine
Box 42: Quick Facts - ImmunoVEX trimelan
Box 43: Quick Facts - OncoVEX GM-CSF
Box 44: Quick Facts - ZADAXIN
Box 45: Developmental History Thymosin alpha1
Box 46: Quick Facts - Alvac-Mage1/Mage3
Box 47: Quick Facts - iboctadekin
Box 48: Quick Facts - PF-3512676
Box 49: Quick Facts - BAY-504798
Box 50: Quick Facts - EMD-273063
Box 51: Quick Facts - Sorefenib
Box 52: Quick Facts - Vitaxin
Box 53: Quick Facts . Bevacizumab
Box 54: Quick Facts - PI88
Box 55: Quick Facts - Didemnin B
Box 56: Quick Facts - KOS 953
Box 57: Quick Facts - Pivanex
Box 58: Quick Facts - Karenitecin
Box 59: Company Statement
Box 60: Quick Facts - Lomeguatrib
Box 61: Quick Facts - PD 0325901
Box 62: Quick Facts - SB 715992
Box 63: Quick Facts - INO 1001
Box 64: Quick Facts - CP 4055
Box 65: Quick Facts - AP 12009
Box 66: Quick Facts - Ecromeximab
Box 67: Quick Facts - ILX 651
Box 68: Quick Facts - Kahalalide F
Box 69: Quick Facts - ABX MA1
Box 70: Quick Facts - MJV 101
Box 71: Quick Facts - Russian Melanoma Vaccine
Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
Box 73: Quick Facts - F 5004
Box 74: KpOmpA Technology
4.2 List of Tables
Table 1: Critical Risk Factors for Development of Melanoma
Table 2: Definition and Description of Stages of Melanoma
Table 3: Prognosis of the 4 Stages of Malignant Melanoma
Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
Table 5: Progress Profile Dacarbazine
Table 6: Progress Profile Cisplatin
Table 7: Progress Profile Carboplatin
Table 8: Progress Profile Carmustine
Table 9: Progress Profile Melphalan
Table 10: Progress Profile Paclitaxel
Table 11: Progress Profile Tamoxifen
Table 12: Progress Profile Temozolomide
Table 13: Progress Profile Vinblastine/Vinorelbine
Table 14: Progress Profile Interferon alfa-2b
Table 15: Development Milestones- Virulizin
Table 16: Development Milestones - Melacine
Table 17: Development Milestones - Alfanative
Table 18: Development Milestones - Proleukin
Table 19: Deployed Strategies for Blocking Angiogenesis
Table 20: Phase III Randomized Studies of Melanoma Vaccines.
Table 21: Tumor antigen based vaccines
Table 22: In vivo Gene Therapy
Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
Table 24: Ex vivo gene therapy loading of antigen presenting cells
Table 25: Overview of Immunostimulants in Development based on Type
Table 26: Overview of Immuno-Biologicals
Table 27: Overview of Gene Therapy Drugs for Immunostimulation
Table 28: MDX-010’s Collaborative History and Landscape
Table 29: Anti-angiogenisis Drugs under Development
Table 30: Overview Apoptopic Inducer Drugs
Table 31: Overview of Small Molecule Drugs
Table 32:Selected Regulatory Progress of Sorafenib
Table 33: Selected Regulatory Progress of Didemin B
Table 34: Overview of Various Biological Drugs in Development for Melanoma

ABX MA1, Alfanative , ALLOVECTIN-7, AP 12009, Avastin, BAY 504798, Canvaxin, Carboplatin, Carmustine, Ceplene Maxamine, Cisplatin, CP 4055, Dacarbazine, Dexosome, Didemnin B, Ecromeximab, Elea Vaccine, EMD 273063, Enhanzyn, F 50040, Genasense, GMK, GV 1001, GVAX, Iboctadekin, ILX 651, INGN 241, INO 1001, Intron A, Kahalalide F, Karenitecin, KOS 953, Lenalidomide, Lomeguatrib, MDX-010, Melacine, Melphalan, MJV 101, M-VAX, NOVOVAC-M1, NY-ESO-1 ISCOMS, Oncophage, OncoVax, OncoVEXGM-CSF, Paclitaxel, PD 0325901, Peginterferon alfa-2b, Pivanex, Proleukin , ProMune, QS-21, SB 249553, SB 715992, Sorafenib, Talabostat, Tamoxifen, Temozolomide, Temozolomide, Uvidem, Vinblastine/Vinorelbine, Virulizin, Vitaxin, Zadaxin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Melanoma - Targeted Therapeutics.
    To find out more about Melanoma - Targeted Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Melanoma - Targeted Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More


Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer. Learn More

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Pancreatic Cancer, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More